Open AccessPembrolizumab for Overall Survival in Hepatocellular Carcinoma
Author(s) -
Mark L. Fuerst
Publication year - 2021
Publication title -
oncology times
Language(s) - English
Resource type - Journals
eISSN - 1548-4688
pISSN - 0276-2234
DOI - 10.1097/01.cot.0000735072.57343.f6
Subject(s) - medicine , hepatocellular carcinoma , sorafenib , pembrolizumab , cohort , response evaluation criteria in solid tumors , clinical endpoint , oncology , gastroenterology , liver cancer , cancer , progressive disease , surgery , clinical trial , immunotherapy , chemotherapy